Lucentis是一种人源化的治疗性抗体片段，旨在阻断所有生物活性形式的血管内皮细胞生长因子A（VEGF-A），该因子的水平在湿性AMD和其他多种眼科疾病 ...

FDA认为，当Cimerli和Lucentis交替使用或转换时，系统抗药抗体（ADA）和眼内炎症产生临床有效免疫原反应的风险较低，“一项比较免疫原性、药代动力 ...

据悉，Lucentis (雷珠单抗)是由罗氏制药公司旗下基因泰克制药公司研发，已经获得两种眼科病症的处方药物许可。 美国食品和药物监管局称，Lucentis (雷珠单抗)获得批准用于治疗糖尿病性黄斑水肿病症，据悉这种病症极易导致处于工龄阶段的人群失明。

Lucentis is a vascular endothelial growth factor (VEGF) inhibitor which was first approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (AMD) in June 2006.

Review Published: 11 January 2008 Looking beyond Lucentis on the management of macular degeneration E C Fletcher & N V Chong Eye 22, 742–750 (2008) Cite this article ...

Basel, March 20, 2014- Novartis has announced the launch of the Lucentis ® (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS, which ...

At 24 months, 33.6 percent of patients (42/125) who received 0.3 mg Lucentis and 45.7 percent of patients (58/127) who received 0.5 mg Lucentis were able to read at least 15 more letters on the ...

Genentech’s Lucentis is likely to lose about $1 billion in sales due to competition from an upstart drug, combined with government mandates to use sister drug Avastin, an analyst predicts. Within four ...

Lucentis, which is made by S. San Francisco-based Genentech, is the first approved treatment to restore sight in a significant percentage of patients afflicted with the disease.

An FDA advisory panel recommended Thursday that Genentech Inc.'s eye drug Lucentis be approved for some diabetes patients who have lost their sight. An FDA advisory panel recommended Thursday that ...

Biogen Inc. BIIB and privately-held Samsung Bioepis announced that the FDA has approved their biosimilar, Byooviz (ranibizumab-nuna) referencing Roche ’s RHHBY eye drug, Lucentis (ranibizumab).